{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:42:35Z","timestamp":1786995755628,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.pnpbp.2004.06.020","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T12:58:01Z","timestamp":1093957081000},"page":"1213-1219","source":"Crossref","is-referenced-by-count":64,"title":["Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism"],"prefix":"10.1016","volume":"28","author":[{"given":"Dieter","family":"Naber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2004.06.020_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib2","unstructured":"American Psychiatric Association, 2003. Practice guideline for the treatment of patients with schizophrenia: III. Treatment principles and alternatives (http:\/\/www.psych.org\/clin_res\/pg_schizo_3.cfm)."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib4","first-page":"S186","article-title":"Meta-analysis of prolactin effects with aripiprazole","volume":"5","author":"Carson","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"issue":"Suppl. 12","key":"10.1016\/j.pnpbp.2004.06.020_bib6","first-page":"17","article-title":"Adverse effects of the atypical antipsychotics","volume":"59","author":"Collaborative Working Group on Clinical Trial Evaluations","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","article-title":"New atypical antipsychotic medications","volume":"32","author":"Jibson","year":"1998","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib9","first-page":"S186","article-title":"Meta-analysis of weight effects with aripiprazole","volume":"5","author":"Jody","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib12","doi-asserted-by":"crossref","first-page":"104s","DOI":"10.1016\/S0924-9338(02)80470-9","article-title":"Neurocognitive effects: aripiprazole vs olanzapine in stable psychosis","volume":"17","author":"Kern","year":"2002","journal-title":"Eur. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib13","first-page":"103s","article-title":"Aripiprazole: a dopamine\u2013serotonin system stabilizer","volume":"17","author":"Kikuchi","year":"2002","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib14","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","author":"Kujawa","year":"2002"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib15","first-page":"S3","article-title":"Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects","volume":"2","author":"Leysen","year":"1998","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib16","first-page":"S186","article-title":"Meta-analysis of the efficacy of aripiprazole in schizophrenia","volume":"5","author":"Lieberman","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2004.06.020_bib18","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1016\/S0924-977X(01)00110-9","article-title":"Good tolerability equals good results: the patient's perspective","volume":"11","author":"Naber","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib19","series-title":"Novel Antipsychotic Drugs","first-page":"99","article-title":"Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia","author":"Naber","year":"1992"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001504-200201000-00006","article-title":"Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration","volume":"15","author":"Naber","year":"2002","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4088\/JCP.v62n1101","article-title":"Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. \u2018Goldilocks\u2019 actions at dopamine receptors","volume":"62","author":"Stahl","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2004.06.020_bib25","first-page":"S186","article-title":"Meta-analysis of cardiac safety with aripiprazole","volume":"5","author":"Stock","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2004.06.020_bib26","article-title":"Broad effectiveness trial with aripiprazole","author":"Tandon","year":"2003"},{"key":"10.1016\/j.pnpbp.2004.06.020_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584604001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584604001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T04:02:14Z","timestamp":1682740934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584604001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0278584604001435"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2004.06.020","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}